GlassScriptPhysician profile
David P Stearnes
NPI 1609910397
$1,396.83
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.25 · 2020: $15.54 · 2021: $262 · 2022: $659 · 2023: $313 · 2024: $73.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $386.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $175.35 | 2021-2023 | Jardiance |
| Abbvie INC. | $130.67 | 2021-2023 | Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.13 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $88.67 | 2022-2023 | Rexulti |
| Esperion Therapeutics, INC. | $75.69 | 2020-2021 | |
| Amgen INC. | $75.63 | 2021-2023 | Prolia, Evenity |
| Cleerly, INC. | $69.55 | 2023-2024 | Cleerly Labs, Cleerly Ischemia |
| Bayer Healthcare Pharmaceuticals INC. | $59.86 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $56.79 | 2019-2022 | |
| Novo Nordisk INC | $54.58 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.96 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $48.70 | 2019-2023 | |
| Pfizer INC. | $48.01 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $42.02 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.45 | 2021-2023 | Gattex |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $29.88 | 2023 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $28.48 | 2022-2023 | |
| Conmed Corporation | $23.23 | 2024 | Airseal |
| Sanofi Pasteur INC. | $19.53 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $19.41 | 2023 | Inpefa |
| Irhythm Technologies, INC. | $18.77 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.32 | 2022 | |
| Daiichi Sankyo INC. | $17.40 | 2022 | |
| Astellas Pharma US INC | $16.49 | 2021 | |
| Abbott Laboratories | $16.45 | 2022 | |
| Bausch Health US, LLC | $15.93 | 2021 | |
| Dexcom, INC. | $14.86 | 2022 | |
| Merck Sharp & Dohme LLC | $13.71 | 2022 | |
| Xeris Pharmaceuticals, INC. | $12.78 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stearnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.